CPS Companion Diagnostic has established a genomics laboratory and bioinformatic services collaboration with one of the world’s leading genetics and genomic labs, SEMA4, a spinout of the Icahn Institute for Genomics and Multiscale Biology from the Mount Sinai Hospital System (the “SEMA4”) (click here). SEMA4 was created to help advance precision medicine with cutting-edge technologies and world-class computational and analytical resources. The collaboration is led by the CPS Companion Diagnostic’s Science Advisory Board, which includes several of the foremost cancer immunotherapy experts from The Tisch Cancer Institute and SEMA4.
The collaboration provides our pharmaceutical and biotech clients with a comprehensive suite of capabilities and services necessary for the development, validation and commercialization of immunotherapy response-predictive companion diagnostics:
Access to Mount Sinai and SEMA4’s world class team of immunology, oncology, genomics and bioinformatics scientists and medical professionals.
Access to CPS Companion Diagnostic’s unique, patent-pending immunotherapy blood-based biomarkers. These response predictive biomarker capabilities address checkpoint inhibitors, combination therapies and personalized therapeutic cancer vaccines.
Access to SEMA4’s state-of-the-art technical resources, including next generation platforms from Applied Biosystems, Illumina and Pacific Biosciences. Technology platforms (click here) available in particular to CPS Companion diagnostics under this Collaboration include:
Supercomputer High-performance Computing Infrastructure
The collaboration team of CPS Companion Diagnostic and SEMA4 welcome the opportunity to meet with pharmaceutical and biotech companies to explore programs for the commercialization of response-predictive companion diagnostics for their immunotherapy drugs in the market and in their pipelines. For inquiries, please contact Karl G. Wassmann, President of CPS Companion Diagnostics, at firstname.lastname@example.org or (774) 893-4313.